Short-Term Use of GLP-1 Weight Loss Drugs for Aesthetic Goals Raises Medical Concerns
A growing number of people are using GLP-1 medications like tirzepatide and semaglutide off-label to lose weight quickly for events such as weddings. Researchers warn that cycling on and off these drugs may reduce their effectiveness, cause rapid weight regain, and lead to health deterioration.
Beverley Smith, a 32-year-old woman in Halifax, has lost more than 30 pounds since starting the drug tirzepatide in March to prepare for her wedding next summer. She is part of a growing trend of individuals using GLP-1 weight loss medications off-label for short-term aesthetic goals rather than for chronic conditions like Type 2 diabetes or obesity.
GLP-1 drugs work by mimicking the hormone glucagon-like peptide-1 to suppress blood sugar, control appetite, and slow stomach emptying. While research suggests long-term use may help curb substance use disorders, cut the severity of sleep apnea, or reduce cancer risk when managing obesity, medical experts caution against using them without proper assessment for minor, short-term weight loss.
Dr. Caroline Kramer advises that patients wanting to shed small amounts of weight for short-term events like weddings should not use these medications without proper assessment, as it may cause more harm than good. Dr. Sean Wharton warns that people using GLP-1s off-label for short-term aesthetic goals face "buyer beware" risks because negative aspects are not fully known.
Discontinuing treatment is common. A recent study from a Danish research team found that roughly half of adults stopped semaglutide treatment within 12 months. However, stopping the medication can lead to rapid weight regain and the return of health issues such as high blood pressure. Potential adverse events associated with the drugs include stomach upset, acute pancreatitis, and rare vision loss.
Cycling on and off the drugs may also diminish their effectiveness over time. Research by Dr. Thomas Leung on mice showed that those who cycled GLP-1 use every two weeks struggled to lose weight compared to those on continuous treatment, remaining 20 per cent heavier even after two months of consistent use.
To address how to safely stop using GLP-1 drugs, Dr. Daniel Drucker and Dr. Caroline Kramer are leading a 16-week randomized controlled trial at Mount Sinai Hospital to determine if slowly tapering off GLP-1s is better than abruptly stopping. The shift in usage from medical necessity to the "aesthetic medicine space" highlights the need for new treatment guidelines addressing safe discontinuation.